GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (STU:2VT0) » Definitions » Research & Development
中文

Lipocine (STU:2VT0) Research & Development

: €5.60 Mil (TTM As of Dec. 2023)
View and export this data going back to 2016. Start your Free Trial

Research & Development is the aggregate amount of research and development expenses during the year. Lipocine's Research & Development for the three months ended in Dec. 2023 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was €5.60 Mil.

Lipocine Research & Development Historical Data

The historical data trend for Lipocine's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lipocine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.90 - 2.70 -

Lipocine Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipocine  (STU:2VT0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lipocine Research & Development Related Terms

Thank you for viewing the detailed overview of Lipocine's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipocine (STU:2VT0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (STU:2VT0) » Definitions » Research & Development
Comparable Companies
SNTI ALZN TNXP LABP OTLC PHGE MLCT GNPX GOVX VBLT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
LPCN:USA
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Website
http://www.lipocine.com
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.

Lipocine (STU:2VT0) Headlines

No Headlines